Biomedical subjects

M E Lippman

Publications and source records attributed to M E Lippman.

346 records · Page 20Linked to original sources

PubMedDate not supplied

Progesterone receptors in advanced breast cancer.

Progesterone receptor (PR) assay was performed on tumor specimen obtained from 145 women consisting of 82 women with advanced breast cancer and 73 women with early breast cancer (EBC). Advanced breast cancer patients consisted of 50 (61%) of 82 women with advanced primary breast cancer (APBC) and 32 (39%) women with recurrent or secondary breast cancer (SBC). Of 82 advanced breast cancer, 35 (42.7%) were PR+. These consisted of 21 APBC and 14 SBC patients. 43 (59%) of 73 EBC patients had PR+ tumors. Quantitative value of PR correlated with age in overall and in all groups. There was also a significant difference in PR quantitative value between PR+ tumors and PR- tumors. Finally premenopausal APBC patients with PR+ tumors had a 2:1 survival advantage over those with PR- tumors. PR assay is as an invaluable a tool as ER assay in the management of breast cancer.

Adult↗

PubMedDate not supplied

Mitogenic regulation of normal and malignant breast epithelium.

The multiple roles of both estrogenic and polypeptide regulators of mammary epithelial cell growth are reviewed in this article. Effects of both steroidal and peptide hormones are complex and involve multiple interactions with malignant cells and non-malignant host components. Initial carcinogenesis and progression of mammary epithelium to cancer probably require both proliferative stimuli (estrogen, polypeptide growth factors) and genetic damage. This condition may lead to qualitatively different hormonal responses (hormone-responsive cancer). Estrogens can be shown to induce growth-regulatory polypeptide growth factors and interact with them in hormone-dependent breast cancer. Progression of hormone-dependent (estrogen-responsive) breast cancer to hormone independence probably involves multiple mechanisms, including oncogene activation, loss of the estrogen receptor, or loss of hormone responsivity of other gene products. One direction for further therapies may be blockade of hormonal stimulation and interference with necessary activated or induced components of malignant progression such as oncogenes or polypeptide growth factor-receptor systems.

Animals↗

PubMedDate not supplied

Women and breast cancer.

One in every 12 women will develop breast cancer; the incidence increases with age, dietary fat intake, caloric intake, height, and weight. The 10-year survival rate of breast cancer patients who refuse therapy is virtually zero. Segmental mastectomy plus radiation and lumpectomy, combined with systemic (adjuvant)chemotherapy, are alternatives under investigation at the National Institutes of Health that may increase the survival rate by decreasing metastatic complications.

Adult↗

PubMedDate not supplied

Management of advanced breast cancer in Africa: strategies in the absence of hormone receptor assay data.

The oncologist in Africa and many other Third World countries is hampered in the management of breast cancer by the absence of hormone receptor assays in most teaching hospitals. The little information that is available in the literature on hormone receptors in black, breast cancer patients as well as other available hormone receptor information can serve as a data base for the development of a rational approach to this management dilemma. Using the available information, an approach, in the form of a flow chart, has been developed for the management of breast cancer in Africa. It is further suggested that breast cancer should be managed using protocols designed to answer various questions about breast cancer in Africa.

Adult↗